Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00786643 · ClinicalTrials.gov registry record · Phase 2
Study of Gamma Interfereon in Metastatic Colorectal Carcinoma
A Phase 2 study, sponsored by Accelerated Community Oncology Research Network.
- Completed
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
NCT00786643 is a Phase 2 study that has completed, run by Accelerated Community Oncology Research Network. The registered enrollment target is 48 participants.
The verdict
NCT00786643, a Phase 2 study, has completed, sponsored by Accelerated Community Oncology Research Network.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
Study Summary
The purpose of this study is to evalute the response and toxicity of metastatic colorectal cancer patients to the regimen of gamma interferon added to bolus and infusional 5-fluorouracil and leucovorin (GFL) with or without bevacizumab.
Interventions
- DRUG Bevacizumab
- DRUG 5-Fluorouracil
- DRUG Leucovorin (LV)
- DRUG Gamma-Interferon-1b (IFN-γ)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2006-02 |
| Est. Completion | 2010-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00786643
The ClinicalTrials.gov registry entry for NCT00786643 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Accelerated Community Oncology Research Network, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Bevacizumab is the first listed.
NCT00786643 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00786643 about?
NCT00786643 is a clinical study titled "Study of Gamma Interfereon in Metastatic Colorectal Carcinoma". The purpose of this study is to evalute the response and toxicity of metastatic colorectal cancer patients to the regimen of gamma interferon added to bolus and infusional 5-fluorouracil and leucovorin (GFL) with or without bevacizumab.
What is the current status of trial NCT00786643?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2006-02. Estimated completion is 2010-03.
What interventions are being tested in trial NCT00786643?
The interventions under investigation include: Bevacizumab (DRUG), 5-Fluorouracil (DRUG), Leucovorin (LV) (DRUG), Gamma-Interferon-1b (IFN-γ) (DRUG).
Who is sponsoring clinical trial NCT00786643?
This trial is sponsored by Accelerated Community Oncology Research Network, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.